Floatz logo

TCRzeta-CD19t-expressing T-lymphocytes

Stage IV Prostate Cancer AJCC v8

City of Hope Medical CenterPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

513 Active assets in the Stage IV Prostate Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Avodart
Bay State Clinical Trials, Inc.
Phase 4BBB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Degarelix
Bayer
Phase 4BBB
PROPOFOL
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
AVOLVE
Masonic Cancer Center, University of Minnesota
Phase 4BB

View all 50 →

Same molecule, other indications

TCRzeta-CD19t-expressing T-lymphocytes is also rated in:

metastatic prostate carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
castration-resistant prostate carcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →